StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Research analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report issued on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Up 1.7 %

ENZ stock opened at $0.53 on Wednesday. Enzo Biochem has a 1 year low of $0.41 and a 1 year high of $1.40. The company has a fifty day simple moving average of $0.66 and a 200 day simple moving average of $0.95.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Hedge Funds Weigh In On Enzo Biochem

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mink Brook Asset Management LLC bought a new stake in shares of Enzo Biochem during the 4th quarter worth $577,000. Wittenberg Investment Management Inc. lifted its position in Enzo Biochem by 60.1% during the 4th quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock worth $134,000 after acquiring an additional 70,400 shares during the last quarter. Virtu Financial LLC acquired a new position in Enzo Biochem during the 4th quarter worth $35,000. Lepercq De Neuflize Asset Management LLC bought a new stake in Enzo Biochem during the fourth quarter valued at about $88,000. Finally, Geode Capital Management LLC grew its position in shares of Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the last quarter. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.